PT-141 dosage
Also known as: bremelanotide, Vyleesi
What is PT-141?
PT-141 is the development name for bremelanotide, a synthetic peptide closely related to Melanotan II. It was first approved in the US in 2019 and is sold as Vyleesi, an injection given under the skin.
How it works
Bremelanotide activates melanocortin receptors, chiefly the MC1 and MC4 types. The FDA label states that the way it improves low sexual desire in women is unknown; its action on MC1 increases the skin pigment melanin.
What the evidence shows
Approval rested on two identical 24-week Phase 3 trials in more than 1,200 premenopausal women with hypoactive sexual desire disorder (HSDD), meaning persistent low desire that causes distress. Desire scores rose by 0.5 to 0.6 points with Vyleesi versus 0.2 with placebo, and distress scores fell by 0.7 versus 0.4. There was no significant difference in the number of satisfying sexual events, and roughly 40% of women on Vyleesi left the trials early. Earlier studies tested a nasal form in men with erectile dysfunction, but it is not approved for men.
Reported side effects
- Nausea (40% of patients in trials)
- Flushing (about 20%)
- Injection site reactions (about 13%)
- Headache (about 11%)
- Vomiting (about 5%)
- Patches of darkened skin, called focal hyperpigmentation (1%)
Cautions
- Contraindicated in people with uncontrolled high blood pressure or known cardiovascular disease.
- Each dose temporarily raises blood pressure and lowers heart rate, usually returning to baseline within 12 hours.
- Skin darkening was far more common with daily use in one study (38% after 8 consecutive daily doses), is more likely in darker skin, and did not always resolve.
- It may significantly reduce absorption of oral naltrexone and can slow absorption of other medicines taken by mouth.
- The label advises using effective contraception and stopping if pregnancy is suspected.
Legal and regulatory status
FDA-approved as Vyleesi for premenopausal women with acquired, generalized hypoactive sexual desire disorder that causes marked distress and is not due to a medical or psychiatric condition, relationship problems, or a drug. It is not indicated for postmenopausal women, for men, or to enhance sexual performance.
Common questions
Is PT-141 the same as Vyleesi?
PT-141 is the earlier development name for bremelanotide, the active ingredient in Vyleesi. Vyleesi is the FDA-approved product, and it is approved only for premenopausal women with hypoactive sexual desire disorder.
Is PT-141 approved for men?
No. The FDA label states that Vyleesi is not indicated for men. Earlier studies tested a nasal form of bremelanotide in men with erectile dysfunction, but there is no approved product for men.
What are the most common side effects of PT-141?
In the Phase 3 trials, nausea was the most common, affecting 40% of women, followed by flushing, injection site reactions, headache and vomiting. Each dose also temporarily raises blood pressure.
Sources
PT-141 reviews and Q&A
No reviews or questions yet. Be the first.
Get the printable dosing chart
All 50 peptides on a few pages, as a PDF. We’ll also email you when a peptide’s approval status or dosing changes.
More in Sexual, hormonal & skin
Compare PT-141
Reference only, not medical advice. Doses marked FDA-approved come from the US prescribing label. Doses marked Not approved are ranges reported from small studies or community use and have not been established as safe or effective in humans. Check anything here with a licensed clinician before acting on it. Read the full disclaimer.